Agios Pharmaceuticals on Monday saw its stock price drop by more than 24% as it disclosed that its oral candidate for the blood disorder thalassemia has been submitted to regulators ...
READ MORENovartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, bolstering the drug’s case against AstraZeneca’s competing ...
READ MOREThe FDA on Thursday released new details on how it plans to expedite the withdrawal of certain accelerated approvals when drugs fail to show clinical benefit in confirmatory trials, as ...
READ MORELegislation targeting popular Chinese biotech contractors like WuXi AppTec wasn't included in must-pass defense legislation that represented its best chances as this session of Congress ...
READ MORE